ArticleInternational journal of hypertension2012
Protective Role of the ACE2/Ang-(1-9) Axis in Cardiovascular Remodeling.
Article in International journal of hypertension, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 65 citations in OpenAlex.
- Angiotensin II and Cardiovascular Disease: Balancing Pathogenic and Protective Pathways.Current issues in molecular biology · 2025Review
- Novel insights into the central protective role of ACE2 in diabetic cardiomyopathy: from underlying signaling pathways to therapeutic perspectives.Molecular and cellular biochemistry · 2025Review
- Autophagy fine-tuning by angiotensin-(1-9) in cultured rat cardiomyocytes.Frontiers in cardiovascular medicine · 2025Article
- Special Issue: "Enzymes and Enzyme Inhibitors-Applications in Medicine and Diagnosis 2.0".International journal of molecular sciences · 2024Article
- Novel Insights into the Cardioprotective Effects of the Peptides of the Counter-Regulatory Renin-Angiotensin System.Biomedicines · 2024Review
- Angiotensin-Converting Enzyme 2 (ACE2) Signaling in Pulmonary Arterial Hypertension: Underpinning Mechanisms and Potential Targeting Strategies.International journal of molecular sciences · 2023Article
- The RAAS Goodfellas in Cardiovascular System.Journal of clinical medicine · 2023Review
- The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies.Cancer cell international · 2023Review
- Research Progress on Pulmonary Arterial Hypertension and the Role of the Angiotensin Converting Enzyme 2-Angiotensin-(1-7)-Mas Axis in Pulmonary Arterial Hypertension.Cardiovascular drugs and therapy · 2022Review
- Simian Immunodeficiency Virus Infection Mediated Changes in Jejunum and Peripheral SARS-CoV-2 Receptor ACE2 and Associated Proteins or Genes in Rhesus Macaques.Frontiers in immunology · 2022Article
- COVID-19 and renin angiotensin aldosterone system: Pathogenesis and therapy.Health science reports · 2021Review
- ACE2: a key modulator of the renin-angiotensin system and pregnancy.American journal of physiology. Regulatory, integrative and comparative physiology · 2021Article
- COVID-19 and male reproductive system: pathogenic features and possible mechanisms.Journal of molecular histology · 2021Review
- Classical and Counter-Regulatory Renin-Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology.CJC open · 2021Review
- Which ones, when and why should renin-angiotensin system inhibitors work against COVID-19?Advances in biological regulation · 2021Review
- Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Renin-angiotensin system at the interface of COVID-19 infection.European journal of pharmacology · 2021Review
- COVID-19 2020: The Experience of a London Teaching Hospital's Nephrology Service.Kidney & blood pressure research · 2021Article
- COVID-19 and Hypertension: The What, the Why, and the How.Frontiers in physiology · 2021Review
- Moderate Intensity Aerobic Exercise Potential Favorable Effect Against COVID-19: The Role of Renin-Angiotensin System and Immunomodulatory Effects.Frontiers in physiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite reduction in cardiovascular (CV) events and end-organ damage with the current pharmacologic strategies, CV disease remains the primary cause of death in the world. Pharmacological therapies based on the renin angiotensin system (RAS) blockade are used extensively for the treatment of hypertension, heart failure, and CV remodeling but in spite of their success the prevalence of end-organ damage and residual risk remain still high. Novel approaches must be discovered for a more effective treatment of residual CV remodeling and risk. The ACE2/Ang-(1-9) axis is a new and important target to counterbalance the vasoconstrictive/proliferative RAS axis. Ang-(1-9) is hydrolyzed slower than Ang-(1-7) and is able to bind the Ang II type 2 receptor. We review here the current experimental evidence suggesting that activation of the ACE2/Ang-(1-9) axis protects the heart and vessels (and possibly the kidney) from adverse cardiovascular remodeling in hypertension as well as in heart failure.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.